tacrolimus + biologics

Tacrolimus + biologics is a combination regimen utilizing **tacrolimus**, an immunosuppressive calcineurin inhibitor, with one or more **biologic agents** for enhanced or synergistic immunosuppression. It is primarily considered in the management of conditions requiring intensive immune modulation, such as organ transplantation or autoimmune disease. Tacrolimus acts by inhibiting calcineurin via binding to FKBP-12, suppressing T cell activation and interleukin-2 transcription. Biologics—such as monoclonal antibodies or recombinant proteins—have diverse mechanisms, typically targeting specific immune cell receptors or cytokines to modify immune pathways. Combining tacrolimus with biologics confers additive and sometimes synergistic effects on immune suppression, potentially improving disease control but requiring close management of infection risk and drug interactions.

Brand names

tacrolimus + biologics

Other names

tacrolimus + biologics